Jyong Biotech Ltd. (MENS): Total Liabilities
$45.68M
As of 2025-12-31
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $45.68M | +6.5% | 2026-05-15, Balance as of period end |
| 2024-12-31 | $42.88M | n/a | 2026-05-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | $45.68M | +6.5% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $7.76M | +13.9% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $4.23M | -8.4% |
| Incannex Healthcare Inc. (IXHL) | 2025-06-30 | $7.06M | +21.1% |
| Nexentis Technologies Inc. (NXTS) | 2025-12-31 | $4.67M | +424.1% |
| Quoin Pharmaceuticals Ltd. (QNRX) | 2025-12-31 | $7.27M | +11.8% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | $89.71M | -0.6% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $85.04M | +6.2% |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $1.34M | +32.0% |
Compare MENS, ABVC, ANVS, IXHL side by side · Screen every company in Pharmaceutical Preparations ↗